Trial Profile

A prospective multicenter cohort study assessing the impact of patient age and comorbidities on safety and effectiveness outcomes in patients of Inflammatory Bowel Disease treated with Vedolizumab and Ustekinumab

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Focus Adverse reactions; Therapeutic Use

10 Jun 2021 Results of systematic review and meta-analysis of four studies assessed to compare maternal and fetal adverse outcomes in pregnancies of women with inflammatory bowel disease exposed to vedolizumab versus those on other treatment, published in the Journal of Gastroenterology and Hepatology.
14 Sep 2020 New trial record
09 Sep 2020 Results published in the Alimentary Pharmacology and Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com